Search research articles
Contact Us
Filters
Showing results (31-40 of 703) with videos related to
Page
of 71
Sort By:
Cellular Immunology
|
September 1, 1985
The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes
E A Grimm, D J Wilson
Annals of the New York Academy of Sciences
|
January 25, 2002
Occurrence of pharmaceutical contaminants and screening of treatment alternatives for southeastern Louisiana
G R Boyd, D A Grimm
Cancer Immunology, Immunotherapy : CII
|
September 1, 1993
Cytokine combinations in immunotherapy for solid tumors: a review
K M Heaton, E A Grimm
American Journal of Public Health
|
January 1, 1978
Evaluation of the localization auditory screening test in children 6-18 months of age
C H Tillis, W A Grimm
Neurology
|
August 29, 2007
Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme
Sean A Grimm, Lisa M DeAngelis
Journal of the American College of Cardiology
|
August 28, 2010
Extending the use of cardiac resynchronization therapy: do we need a new algorithm?
Thomas H Marwick, Richard A Grimm
Journal of Cellular Biochemistry
|
April 1, 1991
The IL-2 mediated amplification of cellular cytotoxicity
E A Grimm, L Owen-Schaub
Immunology Series
|
January 1, 1989
Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system
J B Blacklock, E A Grimm
CNS Oncology
|
May 28, 2016
Anaplastic astrocytoma
Sean A Grimm, Marc C Chamberlain
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
October 29, 2009
[Risk perception and psychological reactions in public crisis situations using the example of terror attacks]
A Grimm, L Hulse, S Schmidt
Page
of 71
Search research articles
Search
Showing results (31-40 of 703) with videos related to
Sort By:
Page
of 71
Cellular Immunology
|
September 1, 1985
The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral blood lymphocytes
E A Grimm, D J Wilson
Annals of the New York Academy of Sciences
|
January 25, 2002
Occurrence of pharmaceutical contaminants and screening of treatment alternatives for southeastern Louisiana
G R Boyd, D A Grimm
Cancer Immunology, Immunotherapy : CII
|
September 1, 1993
Cytokine combinations in immunotherapy for solid tumors: a review
K M Heaton, E A Grimm
American Journal of Public Health
|
January 1, 1978
Evaluation of the localization auditory screening test in children 6-18 months of age
C H Tillis, W A Grimm
Neurology
|
August 29, 2007
Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme
Sean A Grimm, Lisa M DeAngelis
Journal of the American College of Cardiology
|
August 28, 2010
Extending the use of cardiac resynchronization therapy: do we need a new algorithm?
Thomas H Marwick, Richard A Grimm
Journal of Cellular Biochemistry
|
April 1, 1991
The IL-2 mediated amplification of cellular cytotoxicity
E A Grimm, L Owen-Schaub
Immunology Series
|
January 1, 1989
Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system
J B Blacklock, E A Grimm
CNS Oncology
|
May 28, 2016
Anaplastic astrocytoma
Sean A Grimm, Marc C Chamberlain
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
|
October 29, 2009
[Risk perception and psychological reactions in public crisis situations using the example of terror attacks]
A Grimm, L Hulse, S Schmidt
Page
of 71